Navigation Links
Lilly Highlights Transformation Strategy for Wall Street, Reviews Robust Pipeline and Sets 2009 Financial Guidance
Date:12/11/2008

eeting bode well for the future of our company and the patients we serve."

"The pharmaceutical industry, however, continues to face major challenges, and we must act quickly and decisively to address them," noted Lechleiter. "We must respond to the demand for greater value among payers, providers and patients. We must also prepare for the wave of patent expirations that will come in the early part of the next decade. At Lilly, we recognize those challenges, and also recognize the tremendous opportunities that can be created by a company with a clear vision and a commitment to change. We are fundamentally transforming our business, and are doing so from a position of strength. Our strategy is to create value for our stakeholders by accelerating the flow of innovative new medicines that provide improved outcomes for individual patients."

Pipeline Progress - Expanding Biotech, Reducing Costs and Increasing Productivity

Steven M. Paul, M.D., executive vice president, science and technology and president of Lilly Research Laboratories, explained how Lilly's strategy for research and development is designed to respond to the challenges of pharmaceutical R&D. "Lilly's goal is to substantially improve R&D productivity and reduce late-stage attrition, thereby lowering the cost to bring a new molecular entity (NME) to market, from $1.2 billion in 2007 to $800 million by 2010. Our most recent estimate of $1.0 billion shows that we are making significant progress toward achieving this goal through our R&D transformation."

Dr. Paul then detailed several key U.S. and international examples of FIPNet transformation and their positive impact on R&D productivity. These examples include the sale of Lilly's Greenfield Laboratories site to Covance, the expansion of Chorus, Lilly's virtual drug development organization, the creation of a joint venture in India with Jubilant Organosys, and other
'/>"/>

SOURCE Eli Lilly and Company
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15

Related biology technology :

1. Emisphere Technologies, Inc. and Eli Lilly and Company Settle Ongoing Litigation
2. Lilly Declares Fourth-Quarter Dividend
3. Robert Conley, M.D. to Join Lilly; Will assume a neuroscience leadership role as a Distinguished Lilly Scholar
4. Lilly and BioMS Medical Announce Global Licensing and Development Agreement
5. Daiichi Sankyo, Lilly Submit New Drug Application for Investigational Antiplatelet Drug, Prasugrel, with U.S. Food and Drug Administration
6. In response to a New England Journal of Medicine article published yesterday and subsequent media coverage, Eli Lilly and Company issued the following statement:
7. Lilly Announces Termination of AIR Insulin Program
8. HistoRx and Lilly Extend, Expand AQUA(R) Analysis Partnership
9. Pelikan Technologies and Lilly Form Alliance to Promote Diabetes Education
10. Lilly Reports Solid First-Quarter Results
11. Lilly CEO Praises Massachusetts Leadership in Biotech, Urges Policy Prescriptions to Help Ensure States Investment Generates Dividends and Jobs
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/29/2015)... 2015 /PRNewswire/ - BioAmber Inc. (NYSE: BIOA ) today ... Financial Officer has resigned.  The Company has hired ... retired in December 2014, as full time interim CFO ... Andy Ashworth began his employment ... smooth transition.  Andy was the Company,s CFO from September ...
(Date:7/29/2015)... 2015 Research and ... of the "Global Biosimilars Market, 2015 - ... The Global Biosimilars Market, 2015 - 2025, report ... biosimilars market. With the blockbuster biologics losing patent ... biosimilars are being viewed as viable substitutes to ...
(Date:7/29/2015)... , July 29, 2015  Pfenex Inc. (NYSE MKT: ... results will be released on Thursday, August 13, 2015, ... Time, Pfenex management will host a conference call to ... A press release outlining the financial results and business ... Please call 1-866-376-8058 (US) or 1-412-542-4131 (international) ...
(Date:7/29/2015)... QUEBEC CITY , July 29, 2015 /PRNewswire/ ... (the "Company") today announced it has selected an optimized ... important milestone in the development of a new ... The MAPK pathway represents a prime target for ... significant antitumor activities and survival benefits for B-Raf ...
Breaking Biology Technology:BioAmber Announces Change in Chief Financial Officer 2BioAmber Announces Change in Chief Financial Officer 3Global Biosimilars Market to 2025: Monoclonal Antibodies (mAbs), Insulin, Interferons, G-CSF/ GM-CSF, Erythropoietins and Others 2Global Biosimilars Market to 2025: Monoclonal Antibodies (mAbs), Insulin, Interferons, G-CSF/ GM-CSF, Erythropoietins and Others 3Pfenex To Report Second Quarter 2015 Results and Provide Business Update on Thursday, August 13, 2015 2Aeterna Zentaris Announces Optimized Erk Inhibitor Compounds For Further Development 2Aeterna Zentaris Announces Optimized Erk Inhibitor Compounds For Further Development 3
... Imagine an LED light with 20 times the efficiency ... transmit, and store data 100 times faster than those we ... we could turn waste heat into electricity, or improve the ... more accessible? The (IEE) at the University of ...
... Inc., a company dedicated to advancing orthopedic care ... that it has secured a $2M investment from ... chairman of Liberty Media Corporation. In addition to ... research, the investment will help support the national ...
... 2012   USHIFU, LLC (US HIFU), a world leader ... technologies, announced today that Mark Carol, MD, has ... officer. With more than 25 years of clinical ... will focus on continued development of the company,s ...
Cached Biology Technology:Oracle chairman Jeff Henley makes $50 million gift to UC Santa Barbara 2Oracle chairman Jeff Henley makes $50 million gift to UC Santa Barbara 3Oracle chairman Jeff Henley makes $50 million gift to UC Santa Barbara 4Regenerative Sciences Receives $2M Investment for Orthopedic Stem Cell Initiatives 2US HIFU Adds Mark Carol, MD, As Chief Development Officer 2US HIFU Adds Mark Carol, MD, As Chief Development Officer 3US HIFU Adds Mark Carol, MD, As Chief Development Officer 4
(Date:7/13/2015)... JOSE, Calif. , July 13, 2015 /PRNewswire/ ... leading developer of human interface solutions, today announced ... generation touch and display driver integration (TDDI) product ... is the first to combine Synaptics , ... with proven display driver technology developed in the ...
(Date:7/9/2015)... 9, 2015  Synaptics Inc. (NASDAQ: ... interface solutions, today announced a new Match-in-Sensor™ ... hardware encapsulated fingerprint sensor and matching solution. ... literally off the grid, isolating fingerprint image ... the fingerprint sensor to provide ultimate protection ...
(Date:7/7/2015)... , June 30, 2015 ... announced the addition of the "Capacitive Fingerprint ... To this date, fingerprint sensing technology ... and fingerprint sensors are well developed. This patent ... technology. The domain of capacitive fingerprint ...
Breaking Biology News(10 mins):Synaptics Announces Sampling of Second Generation TDDI Solutions 2Synaptics Announces Sampling of Second Generation TDDI Solutions 3Synaptics Announces World's First Match-in-Sensor Fingerprint Authentication Technology 2Synaptics Announces World's First Match-in-Sensor Fingerprint Authentication Technology 3Worldwide Capacitive Fingerprint Sensors Patent Landscape Market Report 2015-2020 - Main IP Holders include Seiko Epson, AuthenTec, Sony and STMicroelectronics 2
... MUHC have announced Quebec's first successful combined heart/liver transplant. ... from the Institut de cardiologie de Quebec (l'hôpital Laval) ... and liver during a 6-hour operation on April 14, ... procedure involved 15 physicians, surgeons and other health care ...
... used hybridization to transfer useful traits between species. ... aid? In a new study in the June ... University and Rice University), Rebecca A. Randell (Indiana ... how spontaneous hybridization ?known as adaptive trait introgression ...
... astonishing ability to apparently transform into any kind of cell ... with their surroundings - even when they are outside of ... report. , Using an animal model of embryonic stem cell ... answer one of the most fundamental questions in science - ...
Cached Biology News:MUHC announces a transplant first in Quebec 2Medium is the message for stem cells in search of identities 2Medium is the message for stem cells in search of identities 3
(3-[125I]iodotyrosyl26)Galanin, porcine, 370 kBq, 10 uCi. Category: IODINE LIGANDS....
Homo sapiens postsynaptic protein CRIPT Antigen: Recombinant Protein...
Immunogen: Synthetic peptide based on the sequence: SPSSGPSLTADSMWR Storage: -20 C, Avoid Freeze/Thaw Cycles...
Human beta IG-H3 MAb (Clone 348506) Keywords: BIGH3, betaIG-H3 Protein Family: Extracellular Matrix Molecules...
Biology Products: